Press Release

Suven Life Sciences announced its participation in the BIO International Convention 2026 to showcase its differentiated Central Nervous System (CNS) clinical candidates. The company aims to explore strategic partnering, out-licensing, and co-development initiatives for its late-stage clinical assets, including Masupirdine and Samelisant (both in Phase 3) and Ropanicant, which recently reported positive Phase 2b results. Senior management will engage in numerous pre-scheduled meetings with global pharmaceutical and biotechnology companies.